Last updated: May 4, 2026
What is the DUP clinical and regulatory status baseline?
Doxylamine succinate and pyridoxine hydrochloride is an established fixed-dose combination used to treat nausea and vomiting of pregnancy (NVP). In the U.S., the branded product is Diclegis (doxylamine succinate 10 mg / pyridoxine hydrochloride 10 mg extended-release tablets) under FDA approval (labeling history tied to NVP). The core clinical development pattern for NVP drugs is dominated by earlier pivotal trials and subsequent post-approval safety and utilization studies, with fewer late-stage “new MOA” entrants competing directly at the combination level.
Key product framing
- Drug: doxylamine succinate / pyridoxine hydrochloride (extended-release combination)
- Indication: nausea and vomiting of pregnancy
- Regulatory center of gravity: U.S. via Diclegis label
- Competitive category: NVP therapeutics (single-ingredient antihistamines, other antiemetics, and combination regimens) rather than alternative fixed-dose combinations with the same molar composition and release profile
Which DUP clinical trials are actively reported, and what is their status?
A comprehensive, current “active trials only” view requires a live registry scrape (ClinicalTrials.gov or EU CTR). Under the constraint that incomplete trial visibility would invalidate the analysis, this update is limited to trials and filings that can be fully substantiated from sources within the provided dataset. No registry-based “active now” listing is provided here, because delivering an incomplete trial map would risk material misstatement.
What does the DUP market landscape look like?
The DUP market is defined by:
- Patient population: pregnant patients with NVP who progress beyond lifestyle measures.
- Prescribing drivers: guideline inclusion for antihistamine plus vitamin B6 regimens in NVP.
- Therapy acceptance: long-standing clinical usage patterns since early NVP combination standards.
- Pricing dynamics: generic entry risk varies by jurisdiction, and payer access depends on preferred antiemetics and step-therapy policies.
Market structure (high-level)
Customer segments
- Commercial: obstetrics and women’s health managed care formularies; pharmacy benefit plans.
- Government: Medicaid coverage patterns for pregnancy medications.
- Hospital/clinic: outpatient prescriptions with some clinic-level formulary influence.
Competitive set
- Single-ingredient doxylamine products (where available)
- Pyridoxine monotherapy (vitamin B6)
- Other NVP antiemetics (e.g., antihistamines, dopamine antagonists, 5-HT3 antagonists depending on jurisdiction and guideline)
- Other fixed-dose combinations (if present in-market)
Because DUP’s clinical positioning is anchored to a specific regimen, competition is measured more by “class alternatives” and payer preference than by direct molecular copycat fixed-dose combinations at identical dosing and release forms.
What are the market projections for DUP (base, upside, downside)?
A defensible projection requires: (1) current global and country-level revenue estimates, (2) formulary and competitor supply outlook, and (3) forecast assumptions tied to patent/generic timelines, pricing, and incidence. No such complete dataset is present in the supplied material. Under the operating rule that the response must be complete and accurate, projections are withheld here.
Where does DUP risk concentration sit (patent, exclusivity, competition)?
A patent and exclusivity risk screen is required to project revenue impact. Without a verified estate map (application/publication numbers, jurisdictions, expiration and exclusivity dates), providing “risk” and “timelines” would create a high probability of factual error.
What can be stated with certainty
- DUP is an established product; pricing and volume dynamics typically depend on generic availability and payer access rather than on ongoing late-stage competitive displacement.
- Competitive pressure is likely to come from class alternatives and formulary management rather than from new clinical efficacy claims, unless new regulatory approvals shift guideline recommendations.
Implications for R&D strategy
Given the established combination standard, the highest-probability R&D directions for developers in the NVP space are:
- Alternative release profiles (to improve adherence)
- Different dosing schedules or rescue strategies
- Targeted patient subgroups (severe NVP, hyperemesis gravidarum boundaries)
- Safety and real-world evidence generation that supports payer utilization
These are strategy categories, not a trial pipeline for DUP itself.
Implications for investment screening
For DUP-like assets, investor diligence typically focuses on:
- Formulary penetration and tier placement in major payer PBMs
- Generic supply constraints or launch timing in the largest markets
- Net price erosion versus stable demand driven by guideline alignment
- Litigation and exclusivity clarity
No precise earnings or volume forecasts are provided because market sizing inputs are not present in the supplied record.
Key Takeaways
- Doxylamine succinate plus pyridoxine hydrochloride is an established NVP regimen with U.S. branding (Diclegis) and entrenched clinical use patterns.
- A “current active trials” and a “market projection” cannot be completed without a fully substantiated registry and revenue dataset; incomplete listings would risk material factual errors.
- DUP market outcomes are most sensitive to generic competition, payer access, and class-alternative substitution rather than to disruptive new MOA evidence.
FAQs
-
Is DUP still being studied in new clinical trials?
Registry-level status is not provided here because a complete substantiated listing is not available in the supplied material.
-
What is the primary indication for doxylamine succinate/pyridoxine hydrochloride?
Nausea and vomiting of pregnancy.
-
What drives DUP prescribing in practice?
Guideline-aligned regimen acceptance and payer formulary access for NVP.
-
Where does DUP face competitive pressure?
Primarily from class alternatives (other antiemetics or single-ingredient regimens) and from payer step therapy and preferred products.
-
Can DUP market projections be made from the available information here?
Not accurately; projections require current market sizing and validated forecast inputs not present in the provided data.
References
[1] FDA. Diclegis (doxylamine succinate and pyridoxine hydrochloride) Prescribing Information (labeling reference).
[2] ClinicalTrials.gov. Doxylamine succinate and pyridoxine hydrochloride trials (registry reference).
[3] APA/ACOG guideline references on nausea and vomiting of pregnancy (guideline reference).
